Antoinette F. Konski


Antoinette F. Konski is a partner and intellectual property lawyer with Foley & Lardner LLP, and serves as managing partner of the Silicon Valley office. She also served as a co-chair of the firm’s national Life Sciences Industry Team and is the former vice-chair of the firm’s national Chemical, Biotechnology & Pharmaceutical Practice Group.


Representative Experience

Antoinette’s practice focuses on advising clients about the creation, protection, acquisition, and maximization of intellectual property assets in a manner that optimally aligns with their business objectives. She primarily counsels biotechnology, pharmaceutical, and medical device companies on all aspects of obtaining, defending, evaluating, licensing, and enforcing intellectual property rights and patents. Antoinette counsels clients on how to best utilize their intellectual property assets as a powerful tool in effectuating their business strategy, whether that involves gaining a competitive market advantage, establishing or consolidating their market position, or obtaining the maximum value for or commercializing their intellectual property assets.

She manages complex global patent portfolios (having drafted over 600 original patent applications) in diverse technologies, including personalized CAR and NK cell therapy, gene therapy, antibody therapeutics, pharmaceuticals, diagnostics, formulation technology, and medical devices. Antoinette also has specialized expertise in precision/personalized medicine. She has extensive experience in freedom-to-operate and landscape analysis of antibody technologies and cell and gene therapies, which allows her to assist clients in developing innovative, novel, and competitive technologies in these fields.

Antoinette also has significant experience in assisting clients prepare for the diligence of intellectual property assets within the context of various business transactions, including public or private investments, strategic acquisitions, and public offerings.

Antoinette has also successfully represented clients in multiple inventorship disputes, derivation and reexamination proceedings before the United States Patent Office, as well as successfully argued several cases before the United States Patent Trial and Appeal Board.

Representative Recent Transactions

  • Represented a pharmaceutical company recently acquired for $1 billion
  • Represented a medical device company that went public with a valuation of over $2 billion
  • Represented a cell therapy company in connection with equity investment of $36 million
  • Represented a gene therapy company in several rounds of capital raising
  • Represented a stem cell company in several rounds of capital raising
  • Represented a biotechnology company in connection with acquisition of pharmaceutical company
  • Represented CHL Medical Partners in connection with equity investment
  • Represented HealthCare Ventures in connection with Series A equity investment

Awards and Recognition

  • 2013, named one of Silicon Valley’s Women of Influence by the Silicon Valley Business Journal
  • 2011, selected by the Daily Journal as a Top 25 IP Portfolio Manager in California and one of 25 Leading Biotech Lawyers in California
  • Recognized by The Legal 500 for her work in the area of health care – life sciences in 2013, 2014, 2015, and 2016
  • Recognized by The Legal 500 US 2009 Edition
  • Recognized by The Legal 500 US: Volume II: Intellectual Property, Media, Technology, and Telecom 2007 Guide as a top attorney for patent prosecution

Presentations and Publications

Book Chapters

Antoinette has authored several book chapters: Patenting Trends in Chimeric Antigen Receptor Technologies, in Second Generation Cell and Gene-based Therapies (Academic Press, 2020); Inventorship and Authorship, in Intellectual Property in Molecular Medicine (Cold Spring Harbor Laboratory Press, 2014); Derivation and Derivation Proceedings, in America Invents Act: Law & Analysis (Wolters Kluwer Law & Business, 2013); Patenting Stem Cell Technologies: Making a Claim in Colloquium Series on Stem Cell Biology (Morgan & Claypool Publishers, 2013).

Select Publications and Presentations

  • Konski and Lorengo, “Patents and the Pandemic – Patenting Trends Before and After Covid,” 16th Annual Advanced Patent Law Institute, March 23-25, 2021, The University of Texas School of Law and George Mason University
  • Konski, “Can AI Transform Precision Medicine?” Personalized Medicine Bulletin (November 3, 2020)
  • Konski, “Does Payer Coverage Drive Genomic Test Utilization in the United States?” Personalized Medicine Bulletin (August 26, 2020)
  • Konski, “Adjusting to Alice:  USPTO’s View of Its Examination Guidelines,” Personalized Medicine Bulletin (April 28, 2020)
  • Konski, “Utilization of Natural Phenomenon Found Patent Eligible,” Personalized Medicine Bulletin (March 31, 2020)
  • Konski, “USPTO Guidance on Patent-Eligibility of Personalized Therapy,” Personalized Medicine Bulletin (November 12, 2019)
  • Konski, “Advancing Access to Precision Medicine Act – A Bipartisan Bill,” Personalized Medicine Bulletin (March 5, 2018)
  • Konski, “Why the Federal Circuit Revisited Written Description,” Personalized Medicine Bulletin (July 17, 2017)
  • Konski, “Breaking Down Barriers Between Pre-clinical and Clinical Adoption of Personalized Medicine,” Personalized Medicine Bulletin (May 2, 2017)
  • Konski, “Forget Bigger Data – Personalized Medicine Needs Smarter Data to Reach Its Full Potential,” Personalized Medicine Bulletin (April 18, 2017)
  • Konski, “Legal Challenges to Healthcare Reform Threaten Biopharmaceutical Legislation,” GEN (March 2011)
  • Konski, “Defining the Scope of Commercial Success,” InsideCounsel (January 2011)
  • Konski, “Are We There Yet? How to Meet Chinese Patent Law Data Disclosure Requirements,” InsideCounsel (January 2011)
  • Konski, “Federal Circuit Rules on Patent Eligibility After Bilski,” InsideCounsel (December 2010)
  • Konski, “Selling and Testing? Mind the On-Sale Bar,” InsideCounsel (December 2010)
  • Konski and Best, “Stem Cell Funding Controversy Creates Uncertainty for Ongoing and Future Research,” AHLA Connections (December 2010)
  • Konski, “Does the First Sale Doctrine Apply to Imported Goods?” InsideCounsel (November 2010)
  • Konski, “Peer to Patent Announces Third Wave,” InsideCounsel (November 2010)
  • Best and Konski, “An Unclear Future for Stem Cell Research: District Court Orders Federal Government to Halt Embryonic Stem Cell Research Funding,” Foley & Lardner LLP Legal News Alert (August 2010)
  • Waltz and Konski, “The Genomics and Personalized Medicine Act of 2010,” HealthLaw360 (August 2010)
  • Konski, “Reading Tea Leaves: An Update on Personalized Medicine: Innovation, Threats and Opportunities,” Bloomberg’s Intellectual Property Law Report (July 2010)
  • Konski, “Personalized Medicine: Innovation, Threats and Opportunities,” Bloomberg’s Intellectual Property Law Report (July 2010)
  • Konski and Waltz, “The Genomics and Personalized Medicine Act of 2010 Introduced in the House of Representatives,” Foley & Lardner LLP Legal News Alert (June 2010)
  • Konski et al., “Health Care Reform Bill Offers Support for Personalized Medicine,” Foley & Lardner LLP Legal News Alert (April 2010)
  • Best, et al., “District Court Rules That Genes and Genetic Tests are Not Patentable,” Foley & Lardner LLP Legal News Alert (March 2010)
  • Konski et al., “From Speculation to Reality: Personalized Medicine and The Genetic Information and Nondiscrimination Act,” Foley & Lardner LLP Legal News Alert (November 2009)
  • Konski and Spielthenner, “Stem Cell Patents, A Landscape Analysis,” Nature Biotechnology (Vol. 27(8), pages 722-726, 2009)
  • Konski, Brinckenhoff, Nie, “Genes Under the Microscope – Novel or Not?” Intellectual Property Today (July 2009)

Thought Leadership

  • Editor of the firm’s Personalized Medicine Bulletin blog, which follows the evolving development and intellectual property protection of enabling diagnostic methods and therapies
  • Founding member of The Business of Personalized Medicine Conference and serves on the Advisory Board
  • Frequent speaker and author on various patent topics
11 April 2024 Deals and Wins

Foley Represents ARCHIMED in Acquisition of Majority Stake in Innovative Skincare Company Cellese

Foley & Lardner LLP represented global private equity health care specialist ARCHIMED in its acquisition of a majority stake in Cellese, a developer of innovative topical dermo cosmetics sold under the AnteAGE brand name.
Life Sciences test tubes
15 May 2024 Events

Capital Connect: Finance & Funding in Life Sciences

Join Foley & Lardner LLP and Slone Partners in San Francisco for an informative and engaging afternoon exploring the latest trends and strategies in financing within the Life Sciences Industry.
23 January 2024 Deals and Wins

Foley Represents TCGX as Co-Lead Investor in $150M Series B Financing for Alkeus Pharmaceuticals

Foley & Lardner LLP represented TCGX as co-lead investor in the $150 million Series B financing for Alkeus Pharmaceuticals.
18 January 2024 Deals and Wins

Foley Represents NEA as Lead Investor in Comanche Biopharma Series B Round

Foley & Lardner LLP recently represented New Enterprise Associates, Inc. as lead investor in Comanche Biopharma Corp’s $75 million Series B financing.
16 October 2023 Events

Opportunities, Challenges, and Ethical Considerations in the Age of AI

Join us for an engaging and informative CLE presentation that will guide you through real-world scenarios that explore AI through the lens of business opportunities and risks.
27 September 2023 Deals and Wins

Foley Represents Bioluminescence Ventures as Lead Investor in ReCode Therapeutics Series B Funding Extension

Foley & Lardner LLP represented Bioluminescence Ventures as the lead investor in the $50 million Series B funding extension for ReCode Therapeutics.